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Streptococcus pneumoniae (the pneumococ-
cus) is a predominant cause of pneumonia,
meningitis, and bacteremia. It is a leading
killer of children under 5 years of age,
responsible for the deaths of up to 2
million children annually [1]. Most deaths
occur in African and Asian developing
countries; however, pneumococcal disease
is also a significant problem in particular
populations of developed countries, such
as the North American Indians, and
indigenous Alaskans and Australians [1–
3]. Although vaccination is the most cost-
effective method of protection against
pneumococcal disease, cost remains a
barrier, as does vaccine delivery and
efficacy. In this opinion piece, we discuss
the potential complementary role of pro-
biotics to vaccines in preventing pneumo-
coccal disease through targeting the mi-
crobiome of the upper respiratory tract.
A prerequisite for pneumococcal disease
is adherence of the bacterium to host
nasopharyngeal epithelium leading to
colonization (carriage). The mucosal sur-
face and the microbiome of the nasophar-
ynx are thought to protect against carriage
[4]. Vaccination with pneumococcal vac-
cines reduces carriage of the organism,
and the risk of invasive disease caused by
vaccine serotypes and some cross-reactive
non-vaccine serotypes. Moreover, vaccines
generate herd immunity that may protect
unvaccinated individuals against infection
[5].
In North America and other developed
regions, .80% of pediatric invasive pneu-
mococcal disease (IPD) is accounted for by
serotypes contained within the first-gener-
ation seven serotype conjugate vaccine
(PCV7, Prevnar, Wyeth/Pfizer, United
States). In high-risk populations, several
factors diminish the efficacy of pneumo-
coccal vaccines. For example, PCV7
protects against only ,50% of serotypes
causing IPD in developing countries of
Africa and Asia [6]. Pneumococcal conju-
gate vaccines are also too expensive for
resource-poor countries that experience
the overwhelming burden of disease glob-
ally. The GAVI Alliance has made
significant inroads to this problem, pro-
viding access to these and other life-saving
vaccines to children most in need at a cost
of US$1 billion per year [7]. Nevertheless,
complete vaccine delivery is another major
public health challenge. While GAVI is
planning to implement pneumococcal
conjugate vaccines in 19 developing coun-
tries over the next 2 years [8], vaccine
uptake may be more difficult in certain
populations. Amongst indigenous Austra-
lians, ,50% of infants aged 7 months
have received the full three-dose schedule
(at 2, 4, and 6 months) [9], providing
suboptimal protection against colonization
and disease. In many countries, the first
PCV7 dose is received after colonization
has occurred—usually within the first 6
weeks of life—which may further limit the
efficacy of pneumococcal vaccination.
Furthermore, serotype replacement is
considered the most significant problem in
the post-PCV7 era. Elimination of vac-
cine-serotype carriage has provided new
niches for colonization and subsequent
rises in invasive disease with non-PCV7
serotypes [10]. Although licensure of
higher valency PCVs containing ten or
13 serotypes would be expected to reduce
serotype replacement, the emergence of
other invasive serotypes is likely.
Other early life strategies to prevent
pneumococcal disease are needed, partic-
ularly for resource-poor settings. Maternal
and neonatal immunization approaches
are currently under investigation for their
impact on disease during the first weeks of
life. Targeting the microbiome to modu-
late colonization has been postulated as
one mechanism to improve the efficacy of
a range of vaccines against multiple
pathogens [11]. It has now been demon-
strated that in early infancy, colonization
with pneumococci prior to conjugate
vaccination causes impaired immune re-
sponses to the carried serotype [12,13].
Exploiting the beneficial effects of probio-
tics on microbial colonization and immu-
nity represents a novel approach to
prevent or reduce pneumococcal coloni-
zation and disease.
The World Health Organization
(WHO) defines probiotics as live micro-
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organisms that confer a health benefit to
the host and are generally regarded as safe
in humans [14]. Moreover, clinical studies
have confirmed the safety and feasibility of
oral administration of probiotics in infancy
[15,16]. Lactobacillus and Bifidobacterium are
the two most widely studied genera of
probiotic bacteria [17]. Probiotic activity is
highly species- and strain-specific [18,19].
Principal amongst their pleiotropic effects
is the capacity to counteract microbiome
disturbances, suggesting the potential to
modulate pneumococcal colonization
[20]. Indeed, experimental data suggest
that probiotics can influence the profile of
microbial species in the nasopharynx to
reduce pneumococcal colonization [21–
24]. Probiotics also maintain epithelial
barrier integrity and modulate systemic
and mucosal immune responses [14].
Furthermore, probiotic-microbiome cross-
talk is important, as intestinal microbiota
can shape immune responses by control-
ling the relative activity of regulatory T
cells and Th17 cells [25,26]. A paradigm
for the effects of probiotics in modulating
host responses in the nasopharynx to
protect against pneumococcal infection is
proposed in Figure 1. Importantly, while
the mechanisms of action proposed are
largely supported by animal studies, more
research is needed to confirm these effects
in humans.
Probiotics show specificity in their effect
on microbial patterns in the nasopharynx.
Most of the available data is based on
animal models of colonization or disease.
For example, in a mouse model of pneu-
mococcal pneumonia, Lactobacillus lactis
lowered lung colonization and increased
specific IgG and IgA levels in bronchoalve-
olar secretions after challenge with pneu-
mococcus serotype 14 [21], while Lactoba-
cillus fermentum reduced nasopharyngeal
colonization after challenge with pneumo-
coccal serotype 6A [22]. In humans, the
potential for probiotics to have an impact
on airway microbial colonization is less
clear. In 108 adult volunteers given a
probiotic yogurt containing Lactobacillus
rhamnosus GG (LGG), Bifidobacterium sp.
B420, Lactobacillus acidophilus 145, and Strep-
tococcus thermophilus, a significant reduction in
pathogenic bacteria (including Staphylococcus
aureus, S. pneumoniae, beta-hemolytic strepto-
cocci, and Haemophilus influenzae) was ob-
served compared to a standard yogurt [24].
Streptococcus salivarius is suggested to be an
appropriate probiotic species given that it is
a known colonizer of the upper respiratory
tract in humans [27]. It has been shown to
produce bacteriocin-like substances with
inhibitory activities against a number of
important airway pathogens in vitro and in
vivo [27,28] as well as possess immuno-
modulatory properties in vitro [29,30]. In
otitis media-prone children given antibiotics
prior to oral treatment with a powdered S.
salivarius K12 formula, 33% were newly
colonized with K12 while two of 19 children
were shown to expand the pre-existing S.
salivarius population [31]. No impact on
clinical outcomes was reported in this study,
and the small sample size used makes it
difficult to draw meaningful conclusions. In
contrast, when otitis-prone children
(n=155) were given a daily probiotic mix
containing LGG, L. rhamnosus LC705, B.
breve 99, and Propionibacterium freudenreichii JS
for 24 weeks, no effect on nasopharyngeal
carriage of otitis pathogens was observed.
Furthermore, this probiotic formula did not
prevent the occurrence of otitis media in
these children, although there was a trend of
reduced recurrent respiratory infections
[32]. Taken together, the evidence of
probiotic effects in human studies is more
limited compared to animal models and
justifies the continued investigation of
candidate probiotic species such as S.
salivarius and lactobacilli on airway micro-
bial colonization and their mechanisms of
action.
To date, the effect of probiotics on the
gastrointestinal microbiome have provided
the best evidence for host–microbe inter-
actions such as pathogen exclusion, en-
hanced mucus secretion, production of
anti-bacterial factors, and modulation of
host immunity [14]. Probiotics can restore
aberrant microbiota patterns associated
with inflammatory diseases such as
Crohn’s Disease [33] and allergy [17].
Several clinical studies have shown that
infants who later develop atopic dermatitis
have altered microbiota, with greater
numbers of pathogenic clostridial and
staphylococcal species and fewer beneficial
bifidobacteria [34,35]. Importantly, dys-
biosis precedes clinical symptoms of aller-
gy [36], indicating a causal relationship
between altered microbiota and disease.
Administration of LGG modulates the
composition of the intestinal microbiota
in allergic infants, and reduced by half the
incidence of atopic dermatitis in high-risk
infants by age 2 [36,37]. LGG also
corrected dysbiosis and reduced disease
severity in a mouse model of colitis [38].
These data have implications for pneu-
mococcal disease. Importantly, lung im-
munity is affected by the intestinal micro-
biome, which induces Th1 and IgA
responses via specific inflammasomes
[39]. Therefore, modulation of inflamma-
some activity by probiotics represents a
key biological target. The balance between
microbiome status and health are also
linked to the production of potent anti-
inflammatory short-chain fatty acids such
as butyrate and acetate [40]. Probiotics
restore short-chain fatty acid levels, and
the protective effects of Bifidobacteria spe-
cies against enterohemorrhagic E. coli
infection was shown to be dependent on
acetate production [41].
Probiotics also appear to play an impor-
tant role in facilitating mucosal immunity
against infection [42]. Specifically, probio-
tics are demonstrated to be effective vaccine
adjuvants, enhancing IgG- and IgA-specific
responses to parenteral and mucosal vac-
cines such as influenza [43], H. influenzae
type b (Hib) [44], polio [45], rotavirus [46],
and Salmonella typhi [47] in humans. More
studies on the adjuvant properties of
probiotics in humans are needed, as the
effects reported are often variable and have
been based on clinical trials involving small
sample sizes. For example, in the study by
Fang et al. [47], treatment with LGG or L.
lactis did not significantly enhance the IgG
or IgA response to an oral S. typhi Ty21a
vaccine despite LGG increasing S. typhi–
specific IgA antibody secreting cells in a
greater number of subjects than L. lactis or
placebo. Similarly, while supplementation
with a Bifidobacterium longum BL999 and L.
rhamnosus LPR mix to infants doubled the
anti-HBsAg IgG levels following vaccina-
tion compared to placebo, this was not
statistically significant [48]. In a study by
Kukkonen et al. [44], daily administration
of a LGG, L. rhamnosus LC705, B. breve
Bbi99, and Propionibacterium freudenreichii
combination to mothers in the last 4 weeks
of pregnancy, and to their infants for the
first 6 months of life, increased the Hib-
specific IgG response in infants. However,
no change in diphtheria toxoid or tetanus
toxoid IgG levels was observed, suggesting
that the effects of probiotics may vary
depending on the vaccine antigen used.
Recently, Lactobacillus casei was reported to
significantly enhance the pneumococcal
protective protein A (PppA)-specific IgG
and IgA response in the serum and mucosa
following nasal vaccination with PppA and
was associated with a significantly reduced
pathogen load in the nasal lavage by day 42
post-immunization [42]. Despite this, the
adjuvant activity of probiotics following
pneumococcal vaccination in humans is
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unknown and remains an intriguing pros-
pect for further research.
The promising findings of these studies
has made it increasingly clear that signifi-
cant research emphasis on reducing pneu-
mococcal colonization during the neonatal
period is warranted, ideally involving
human clinical trials. Novel early life
strategies that reduce infection with S.
pneumoniae may have important health
benefits, especially in high-risk populations.
The combined effects of modulating the
nasopharyngeal microbiome and enhanced
mucosal immunity justify the continued
investigation of probiotics for protection
against pneumococcal infection.
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Figure 1. Paradigm for the proposed biological effects of probiotic bacteria in protection against pneumococcal infection.
Commensal and/or probiotic bacteria can prevent pathogens (pneumococci) from attaching to and colonizing the respiratory epithelium by
associating with specific cell surface receptors and by enhancing mucus secretion and the production of secretory IgA. Probiotic bacteria interact
with underlying dendritic cells (DCs) which signal to the adaptive immune system to trigger a variety of effector cell types, including Th1, Th2, and
Th17 as well as regulatory T cells and B cells depending on the local cytokine/chemokine microenvironment. Furthermore, probiotic bacteria also
maintain the epithelial barrier integrity by upregulating the expression of specific tight junction proteins on damaged epithelium as a result of
localized inflammatory responses following pathogen (pneumococcal) encounter and invasion. Refer to references [49–52] for more detail on
probiotic–host effects. Th, T helper cell.
doi:10.1371/journal.ppat.1002652.g001
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